GlassScriptPhysician profile
Jordan T Crow
NPI 1174937908
$2,050.38
in general payments reported to CMS, 2019-2025
30 companies · $497 in 2025
The $497 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $28.66 · 2021: $346 · 2022: $408 · 2023: $282 · 2024: $359 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,138.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $563.29 | 2019-2025 | |
| Sage Therapeutics, LLC | $197.15 | 2024-2025 | Zurzuvae |
| Intuitive Surgical, INC. | $176.23 | 2021-2022 | |
| Astellas Pharma US INC | $100.15 | 2023-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $93.24 | 2019-2023 | Gardasil 9 |
| Sumitomo Pharma America, INC. | $90.96 | 2023-2025 | Myfembree |
| Coopersurgical, INC. | $89.03 | 2023-2024 | Mara Console, Paragard T 380a, Paragard T 380a |
| Pfizer INC. | $85.39 | 2022-2025 | |
| Novo Nordisk INC | $81.34 | 2024-2025 | Wegovy |
| Channel Medsystems, INC. | $63.04 | 2021-2023 | |
| Hologic Sales and Service, LLC | $59.20 | 2021-2025 | Aptima, Thinprep 2000 Processor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.50 | 2021-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $42.63 | 2019-2023 | |
| Roche Diagnostics Corporation | $42.38 | 2019 | |
| Supernus Pharmaceuticals, INC. | $36.57 | 2025 | Qelbree |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $30.52 | 2021-2024 | Olympus |
| Myovant Sciences INC. | $29.74 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.16 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $22.49 | 2025 | Exparel |
| Baxter Healthcare | $21.76 | 2024 | Perclot |
| Medtronic, INC. | $21.11 | 2023 | Endo Stitch |
| Boston Scientific Corporation | $18.00 | 2022 | |
| Teleflex LLC | $17.31 | 2025 | Quikclot |
| Medicem INC. | $15.14 | 2024 | |
| Ironshore Pharmaceuticals INC. | $15.07 | 2022 | |
| Minerva Surgical, INC | $14.58 | 2022 | |
| Ethicon US, LLC | $14.45 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.35 | 2022 | |
| Therapeuticsmd, INC. | $11.94 | 2019 | |
| Smith+Nephew, INC. | $11.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Crow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.